Trial · NCT00594815
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
NCT00594815, Not applicable, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2017-04-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma. Trials, record NCT00594815. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00594815
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
- NCT number
- NCT00594815
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 52 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Lymphoma
- Interventions
- Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
- First posted
- 2008-01-16
- Last updated
- 2017-04-06
- Results first posted
- 2017-04-06
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Number of Participants Who Experienced Acute Treatment Related Adverse Events | 2 years | The toxicity of this combined regimen will be measured using the NCI CTC version 2.0. |
| Primary | Progression Free Survival | 2 Years | Overall Progression Free Survival at 2 years |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Total Number of Participants Who Experienced Acute Treatment Related Adverse Events | 2 years | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Progression Free Survival | 2 Years | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Number of Participants Who Experienced Acute Treatment Related Adverse Events | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 52 | Participants | ||
| Progression Free Survival | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 57 | 95% Confidence Interval 44 to 71 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 52 | |
| Overall Study | COMPLETED | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 43 | |
| Overall Study | NOT COMPLETED | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 9 |
Source ClinicalTrials.gov
Adverse events51
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypocalcemia | Metabolism and nutrition disorders | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 36 | 52 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 36 | 52 | |
| other | Hemoglobin/Anemia | Blood and lymphatic system disorders | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 33 | 52 | |
| other | Leukocytes | Immune system disorders | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 31 | 52 | |
| other | SGPT (ALT) | Investigations | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 24 | 52 | |
| other | Lymphopenia | Immune system disorders | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 30 | 52 | |
| other | Neutrophils/granulocytes | Investigations | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 22 | 52 | |
| other | SGOT (AST) | Investigations | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 16 | 52 | |
| other | Platelets | Investigations | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 14 | 52 | |
| other | Hypophosphatemia | Metabolism and nutrition disorders | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 10 | 52 |
1 to 10 of 51Source ClinicalTrials.gov
See all 51 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 13 | 52 |
| Total, other adverse events | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 43 | 52 |
| Total, serious adverse events | Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 22 | 52 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24101038 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00594815
GET https://conductscience.org/api/trials/v1/NCT00594815/events?page=2